RxDoctor Payments Data

Don Beach, MD

Family Medicine · Moulton, ALNPI 1366416943

Payments from drug & device makers

$6,109in general payments, 2019–2025

Across 364 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$902
  • AstraZeneca$901
  • Novo Nordisk$460
  • AbbVie$338
  • Otsuka America Pharmaceutical, Inc.$319
  • Bayer$272
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,094100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,109 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$140,985
Medicare patients
191
Services billed
2,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide173$219,183
FarxigaDapagliflozin Propanediol140$108,080
JardianceEmpagliflozin88$85,183
EliquisApixaban96$74,571
OzempicSemaglutide40$62,864
TrulicityDulaglutide66$62,587
XareltoRivaroxaban56$44,364
VraylarCariprazine Hcl27$37,616
RybelsusSemaglutide21$19,635
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,140
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$16,918
Soliqua 100-33Insulin Glargine/Lixisenatide12$15,778
Bydureon BciseExenatide Microspheres19$15,570
KerendiaFinerenone23$15,438
LinzessLinaclotide21$12,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$902$281,770239 claims
AstraZenecaFarxiga, Breztri Aerosphere$901$124,997163 claims
Boehringer IngelheimJardiance$115$85,18388 claims
Novo NordiskOzempic, Rybelsus$460$82,49961 claims
PfizerEliquis$131$74,57196 claims
AbbVieVraylar, Linzess, Fetzima$338$56,46460 claims
Johnson & JohnsonXarelto$134$44,36456 claims
MerckJanumet Xr, Belsomra$217$18,85339 claims
GSKTrelegy Ellipta$55$17,14028 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$172$15,77812 claims
BayerKerendia$272$15,43823 claims
Eisai Inc.Dayvigo$121$4,14613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Moulton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →